Comprehensive review outlines mechanisms and management of irinotecan-induced neutropenia in cancer treatment, suggesting effective prevention strategies.
Key Points
This review aims to discuss the pathogenesis, risk factors, and management strategies related to irinotecan-induced neutropenia.
Systematic review of literature on irinotecan, its metabolite SN-38, and their effects.
Analysis of risk factors for neutropenia, including drug dosage and genetic polymorphisms.
Evaluation of management strategies such as drug dosage adjustment and use of granulocyte colony-stimulating factor.
Irinotecan and SN-38 were shown to damage hematopoietic stem cells by inhibiting topoisomerase I (p<0.05).
Identified risk factors include higher irinotecan dosage and specific gene polymorphisms (p<0.01).
Recommended preventive strategies lead to a significant reduction in neutropenia incidence among patients.